Ipilimumab + nivolumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
BMS is headquartered in Princeton, New Jersey, the US. For a complete picture of Ipilimumab + nivolumab’s drug-specific PTSR and LoA scores, buy the report here. GlobalData, the leading provider of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback